A novel envelope mediated post entry restriction of murine leukaemia virus in human cells is Ref1/TRIM5α independent

Retrovirology

Volumn 7, Issue , 2010, Pages

  Oliveira, Nidia M M ^a   Trikha, Roochi ^a   McKnight, Áine ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; REDOX EFFECTOR FACTOR 1; RETROVIRUS VECTOR; SMALL INTERFERING RNA; TRIPARTITE MOTIF PROTEIN 5; APEX1 PROTEIN, HUMAN; CARRIER PROTEIN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; TRIM5 PROTEIN, HUMAN; VIRUS ENVELOPE PROTEIN; ZINC FINGER PROTEIN;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; FLOW CYTOMETRY; GIBBON LEUKEMIA VIRUS; GLIOMA CELL; HELA CELL; HUMAN; HUMAN CELL; MURINE LEUKEMIA VIRUS; NONHUMAN; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS CORE; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION; CHEMISTRY; EXPERIMENTAL LEUKEMIA; FELINE IMMUNODEFICIENCY VIRUS; GENETIC REASSORTMENT; GENETICS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 2; IMMUNOLOGY; INNATE IMMUNITY; RETROVIRUS INFECTION; VIRUS INFECTION;

FRIEND MURINE LEUKEMIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HYLOBATIDAE; MIRIDAE; MURINAE; PRIMATES;

CARRIER PROTEINS; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; GENE PRODUCTS, ENV; HELA CELLS; HIV-2; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; IMMUNODEFICIENCY VIRUS, FELINE; LEUKEMIA VIRUS, MURINE; LEUKEMIA, EXPERIMENTAL; REASSORTANT VIRUSES; RETROVIRIDAE INFECTIONS; TUMOR VIRUS INFECTIONS; ZINC FINGERS;

EID: 77957368770     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-7-81     Document Type: Article

References (40)

1. Coffin J. Retroviridae: the viruses and their replication. Field's Virology 1996, 2:1767-1848. Philadelphia, Pa.: Lippincott, Fields B, Knipe DM, Howley PM, Third.
2. Coffin JM. Retrovirus restriction revealed. Nature 1996, 382:762-763. 10.1038/382762a0, 8752269.
3. Tennant RW, Schluter B, Yang W, Brown A. Reciprocal inhibition of mouse leukemia virus infection by Fv-1 allele cell extracts. Proc Natl Acad Sci USA 1974, 71:4241-4245. 10.1073/pnas.71.10.4241, 434367, 4372614.
4. Benit L, De Parseval N, Casella JF, Callebaut I, Cordonnier A, Heidmann T. Cloning of a new murine endogenous retrovirus, MuERV-L, with strong similarity to the human HERV-L element and with a gag coding sequence closely related to the Fv1 restriction gene. J Virol 1997, 71:5652-5657. 191811, 9188643.
5. Best S, Le Tissier P, Towers G, Stoye JP. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 1996, 382:826-829. 10.1038/382826a0, 8752279.
6. Cordonnier A, Casella JF, Heidmann T. Isolation of novel human endogenous retrovirus-like elements with foamy virus-related pol sequence. J Virol 1995, 69:5890-5897. 189468, 7543594.
7. Goff SP. Operating under a Gag order: a block against incoming virus by the Fv1 gene. Cell 1996, 86:691-693. 10.1016/S0092-8674(00)80141-5, 8797814.
8. DesGroseillers L, Jolicoeur P. Physical mapping of the Fv-1 tropism host range determinant of BALB/c murine leukemia viruses. J Virol 1983, 48:685-696. 255401, 6313967.
9. Kozak CA, Chakraborti A. Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance. Virology 1996, 225:300-305. 10.1006/viro.1996.0604, 8918916.
10. Maillard PV, Reynard S, Serhan F, Turelli P, Trono D. Interfering residues narrow the spectrum of MLV restriction by human TRIM5alpha. PLoS Pathog 2007, 3:e200. 10.1371/journal.ppat.0030200, 2156100, 18166079.
11. Lassaux A, Sitbon M, Battini JL. Residues in the murine leukemia virus capsid that differentially govern resistance to mouse Fv1 and human Ref1 restrictions. J Virol 2005, 79:6560-6564. 10.1128/JVI.79.10.6560-6564.2005, 1091700, 15858043.
12. Ulm JW, Perron M, Sodroski J, R CM. Complex determinants within the Moloney murine leukemia virus capsid modulate susceptibility of the virus to Fv1 and Ref1-mediated restriction. Virology 2007, 363:245-255. 10.1016/j.virol.2006.09.048, 17343889.
13. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427:848-853. 10.1038/nature02343, 14985764.
14. Goff SP. Retrovirus restriction factors. Mol Cell 2004, 16:849-859. 10.1016/j.molcel.2004.12.001, 15610729.
15. Towers GJ, Goff SP. Post-entry restriction of retroviral infections. AIDS Rev 2003, 5:156-164.
16. Yap MW, Nisole S, Lynch C, Stoye JP. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA 2004, 101:10786-10791. 10.1073/pnas.0402876101, 490012, 15249690.
17. Diaz-Griffero F, Perron M, McGee-Estrada K, Hanna R, Maillard PV, Trono D, Sodroski J. A human TRIM5alpha B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus. Virology 2008, 378:233-242. 10.1016/j.virol.2008.05.008, 2597210, 18586294.
18. Yan Y, Kozak CA. Novel post-entry resistance to AKV ecotropic mouse gammaretroviruses in the African pygmy mouse, Mus minutoides. J Virol 2008,
19. Yan Y, Buckler-White A, Wollenberg K, Kozak CA. Origin, antiviral function and evidence for positive selection of the gammaretrovirus restriction gene Fv1 in the genus Mus. Proc Natl Acad Sci USA 2009, 106:3259-3263. 10.1073/pnas.0900181106, 2651326, 19221034.
20. Schmitz C, Marchant D, Neil SJ, Aubin K, Reuter S, Dittmar MT, McKnight A. Lv2, a novel postentry restriction, is mediated by both capsid and envelope. J Virol 2004, 78:2006-2016. 10.1128/JVI.78.4.2006-2016.2004, 369432, 14747565.
21. Reuter S, Kaumanns P, Buschhorn SB, Dittmar MT. Role of HIV-2 envelope in Lv2-mediated restriction. Virology 2005, 332:347-358. 10.1016/j.virol.2004.11.025, 15661166.
22. Pineda MJ, Orton BR, Overbaugh J. A TRIM5alpha-independent post-entry restriction to HIV-1 infection of macaque cells that is dependent on the path of entry. Virology 2007, 363:310-318. 10.1016/j.virol.2007.02.002, 2743720, 17350067.
23. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog 2008, 4:e16. 10.1371/journal.ppat.0040016, 2222954, 18248090.
24. Nisole S, Stoye JP, Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 2005, 3:799-808. 10.1038/nrmicro1248, 16175175.
25. Soda Y, Shimizu N, Jinno A, Liu HY, Kanbe K, Kitamura T, Hoshino H. Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem Biophys Res Commun 1999, 258:313-321. 10.1006/bbrc.1999.0633, 10329384.
26. Reil H, Bukovsky AA, Gelderblom HR, Gottlinger HG. Efficient HIV-1 replication can occur in the absence of the viral matrix protein. EMBO J 1998, 17:2699-2708. 10.1093/emboj/17.9.2699, 1170610, 9564051.
27. Kawakami T.G., Buckley P, Huff S. Characterization of a C-type virus associated with gibbon ape lymphosarcoma. Med Primat 1972, 163-168. Proc. Third Conf. Exp. Surg Primates Lyon 1972 part III:.
28. Eglitis MA, Schneiderman RD, Rice PM, Eiden MV. Evaluation of retroviral vectors based on gibbon ape leukamia virus. Gene Therapy 1995, 2:486-492.
29. Lucas ML, Seidel NE, Porada CD, Quigley JG, Anderson SM, Malech HL, Abkowitz JL, Zanjani ED, Bodine DM. Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes. Blood 2005, 106:51-58. 10.1182/blood-2004-11-4491, 1895126, 15774617.
30. Kavanaugh MP, Miller DG, Zhang W, Law W, Kozak SL, Kabat D, Miller AD. Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci USA 1994, 91:7071-7075. 10.1073/pnas.91.15.7071, 44340, 8041748.
31. O'Hara B, Johann SV, Klinger HP, Blair DG, Rubinson H, Dunne KJ, Sass P, Vitek SM, Robins T. Characterization of a human gene conferring sensitivity to infection by gibbon ape leukemia virus. Cell Growth Differ 1990, 1:119-127.
32. Tailor CS, Nouri A, Kabat D. A comprehensive approach to mapping the interacting surfaces of murine amphotropic and feline subgroup B leukemia viruses with their cell surface receptors. J Virol 2000, 74:237-244. 10.1128/JVI.74.1.237-244.2000, 111533, 10590111.
33. Miller DG, Edwards RH, Miller AD. Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus. Proc Natl Acad Sci USA 1994, 91:78-82. 10.1073/pnas.91.1.78, 42889, 8278411.
34. Eiden MV, Farrell KB, Wilson CA. Substitution of a single amino acid residue is sufficient to allow the human amphotropic murine leukemia virus receptor to function as a gibbon ape leukemia virus receptor. J Virol 1996, 70:1080-1085. 189914, 8551566.
35. Kurre P, Kiem H-P, Morris J, Heyward S, Battini J-L, Miller AD. Efficient transduction by an amphotropic retrovirus vector is dependent on high-level expression of the cell surface virus receptor. J Virol 1999, 73:495-500. 103856, 9847355.
36. Marchant D, Neil SJD, McKnight A. Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture. J Gen Virol 2006, 87:411-418. 10.1099/vir.0.81391-0, 16432029.
37. Miller AD, Garcia JV, von Suhr N, Lynch CM, Wilson C, Eiden MV. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991, 65:2220-2224. 240569, 1850008.
38. Miller AD, Chen F. Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry. J Virol 1996, 70:5564-5571. 190516, 8764070.
39. Bock M, Bishop KN, Towers G, Stoye JP. Use of a transient assay for studying the genetic determinants of Fv1 restriction. J Virol 2000, 74:7422-7430. 10.1128/JVI.74.16.7422-7430.2000, 112262, 10906195.
40. Marchant D, Neil SJ, Aubin K, Schmitz C, McKnight A. An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction. J Virol 2005, 79:9410-9418. 10.1128/JVI.79.15.9410-9418.2005, 1181606, 16014904.